319 related articles for article (PubMed ID: 1422665)
21. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
Moser E; Fritsch S; Braun S
Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
[TBL] [Abstract][Full Text] [Related]
22. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake.
Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA
Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584
[TBL] [Abstract][Full Text] [Related]
24. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
[TBL] [Abstract][Full Text] [Related]
25. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Terris DJ
Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
[No Abstract] [Full Text] [Related]
26. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
27. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
28. Iodine-131 treatment of thyroid cancer: absorbed dose calculated from post-therapy scans.
Koral KF; Adler RS; Carey JE; Beierwaltes WH
J Nucl Med; 1986 Jul; 27(7):1207-11. PubMed ID: 3723194
[TBL] [Abstract][Full Text] [Related]
29. [Iodine scintigraphy of differentiated thyroid carcinoma].
Nakata K; Tsukamoto E; Ito K; Kato C; Furudate M
Rinsho Hoshasen; 1988 May; 33(5):589-90. PubMed ID: 3047462
[No Abstract] [Full Text] [Related]
30. Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma.
Siddiqui AR; Edmondson J; Wellman HN; Hamaker RC; Lingeman RE; Park HM; Johnston CC
Clin Nucl Med; 1981 Apr; 6(4):158-61. PubMed ID: 7214770
[TBL] [Abstract][Full Text] [Related]
31. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
32. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
33. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
34. [Carcinoma of the thyroid in childhood].
Sgro M; Spreafico GL; Colombo L; Musazzi R
Minerva Chir; 1979 Jan 15-31; 34(1-2):63-72. PubMed ID: 481764
[No Abstract] [Full Text] [Related]
35. Local reactions to radioiodine in the treatment of thyroid cancer.
Burmeister LA; du Cret RP; Mariash CN
Am J Med; 1991 Feb; 90(2):217-22. PubMed ID: 1996591
[TBL] [Abstract][Full Text] [Related]
36. [Long-term course in differentiated thyroid gland carcinoma].
Rösler H; Birrer A; Lüscher D; Kinser J
Schweiz Med Wochenschr; 1992 Nov; 122(48):1843-57. PubMed ID: 1462145
[TBL] [Abstract][Full Text] [Related]
37. Value of thyroid carcinoma imaging after therapeutic doses of radioiodine.
Balachandran S; Sayle BA
Clin Nucl Med; 1981 Apr; 6(4):162-7. PubMed ID: 7214771
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy].
Schümichen C; Bulczak-Schmidt M; Blattmann H; Pauli-Harnasch C
Nuklearmedizin; 1984 Oct; 23(5):265-9. PubMed ID: 6522276
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary metastases from differentiated thyroid carcinoma demonstrable only by nuclear imaging.
Bonte FJ; McConnell RW
Radiology; 1973 Jun; 107(3):585-90. PubMed ID: 4702537
[No Abstract] [Full Text] [Related]
40. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
Morris LF; Waxman AD; Braunstein GD
J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]